Epithalon dosage has no source document anywhere in the world
That distinction is worth holding onto, because it changes what a quoted figure can possibly be.
Some compounds sold in this market are licensed medicines somewhere else. For those, at least one regulator has assessed a preparation, agreed a purpose and written down an amount. The number does not transfer across a border, and the argument about it is an argument about transferability.
This compound has no such document. It holds no marketing authorisation in any jurisdiction. There is no registered interventional trial to open, so there is no prespecified quantity sitting in a protocol either. Nothing has been assessed, approved or filed anywhere that a figure could be copied from.
So when a provider or a supplier quotes a number, the question is not whether the number travelled correctly. The question is where it came from at all.
Tracing a number back to its first appearance
Follow any figure in circulation backwards and it narrows quickly.
The published work on this compound is concentrated in a single research group, Khavinson and colleagues in St Petersburg, working on pineal peptide preparations and related claims. Their studies used quantities, as all studies do. Those quantities were experimental choices made for a particular design in a particular organism, usually cell culture or rodents.
An experimental quantity is not a recommendation. It is a variable the researchers selected in order to observe something. Nobody in that process was answering the question a consumer is asking, which is how much a healthy adult should use, for how long, to achieve a stated benefit at acceptable risk. That question requires a different kind of study entirely, and it has not been done.
What happened next is the part worth watching. Quantities from research papers were converted, by sellers and by forum custom, into schedules aimed at people. The conversion involved assumptions about scaling between species, about route, about product strength and about who the compound is for. None of those assumptions were tested. Most were never stated. The output looks like a specification and is closer to a guess with a citation attached.
Species scaling is not arithmetic
The step people underestimate is the jump from a rodent to a person, because it looks like multiplication and is not.
Pharmacology does have conventions for relating quantities across species, based on body size and metabolic rate. Those conventions are starting points for designing a first study in humans, used by people who then run the study to find out whether the starting point was any good. They are not a method for producing a consumer figure without ever running the study.
The reason is that species differ in more than mass. They differ in how quickly a peptide is broken down, in what fraction of an administered quantity reaches the tissue of interest, in the composition of the body it distributes through, and in the sensitivity of whatever receptor or process is involved. Any one of those can move the answer substantially, and none of them is known for this compound in humans, because the work has not been done.
So a figure derived from rodent work by scaling is not a translated quantity. It is a hypothesis about a translation, and it has never been tested. A page that presents the output of that calculation as a recommendation has performed a conversion the field would treat as the beginning of an investigation, not the end of one.
Sources of a figure, and what each one vouches for
The bottom two rows are the ones a careful consumer would want, and both are empty. Everything above them derives its apparent authority from the appearance of the two rows that are missing.
| Where the number appears | What produced it | Organism it was chosen for | What it vouches for |
|---|---|---|---|
| A study from the source literature | An experimental design choice | Cultured cells or rodents | That the experiment used it |
| A supplier's suggested use page | Convention, and the study above | Nobody's, once translated | The supplier's willingness to publish it |
| A clinic treatment plan | Provider judgement and precedent | Not derived from a human trial | The provider's opinion |
| A forum consensus | Repetition among users | Unknown | Popularity, which is not evidence |
| An approved label | Regulatory assessment | Humans, for a defined use | Does not exist for this compound |
| A registered trial protocol | Prespecified before enrolment | Humans | No registered trial exists |
Why a clinic here is in the same position you are
This is the uncomfortable part for anyone comparing providers, and it is worth saying without cynicism.
A clinician quoting you a figure is not reading it off anything. They cannot be, because there is nothing to read it off. They are exercising judgement based on what colleagues do, what the supplier suggests, what seems proportionate, and a reasonable instinct that a bounded exposure beats an open ended one. That judgement can be sensible. It is not a dose in the sense the word carries in a pharmacy.
What a provider genuinely adds is elsewhere. They can screen for conditions that make the idea unwise. They can review what else you take. They can ask whether the underlying concern, usually something about ageing or energy or recovery, has a cause that deserves proper assessment. They can take professional responsibility for the encounter and be reachable afterwards. They can refuse.
They cannot verify a vial they did not manufacture, create an approved use, or draw on a safety record that has never been assembled. If two clinics quote you different amounts, neither is closer to a standard, because there is no standard for either to approach.
The particular problem with an outcome measured in decades
Even the normal fallback of judging by results is unavailable here, and the reason is specific to what this compound is sold for.
Someone using an unlicensed compound for pain has a signal: the pain changes or it does not. Someone using one for sleep finds out within a week. The claimed benefits here are about the rate of biological ageing, which is not something a person can observe over a course of use. There is no reading, no threshold, and no point at which an amount reveals itself as too little or too much.
That means self correction is impossible. Whatever quantity someone begins with is the quantity they will continue with, because nothing in their experience will argue for changing it. The usual informal safety net, that a person would notice if something were wrong, has no sensor attached to it.
The same problem cuts the other way. Nothing in a person's experience can confirm that the amount is doing anything either, which is precisely why accounts of this compound lean so heavily on how someone feels rather than on what changed.
Three things a provider can actually answer
Most questions a buyer wants to ask have no answer available to anyone. A few do, and they are worth spending the consultation on.
Who manufactured this batch, and what testing did it receive. This is answerable, it is specific, and the quality of the answer tells you a great deal about the practice. A named manufacturer with batch specific testing is a different proposition from a generic certificate that could belong to any vial.
Where did your figure come from. An honest answer is that it is their judgement, drawing on precedent and caution. That answer is more trustworthy than a citation, because a citation to work in cultured cells or rodents does not support a human quantity, and a provider offering one either knows that or has not looked.
What will you do if something goes wrong. Who do I contact, how quickly, and what would you report and to whom. A practice that has thought about this has thought about the arrangement properly. A practice that has not is selling a product with a consultation attached.